Literature DB >> 24122416

Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: review of animal models.

Félix Gremonprez1, Wouter Willaert, Wim Ceelen.   

Abstract

The development of suitable animal models is essential to experimental research on intraperitoneal chemotherapy (IPC). This review of the English literature (MEDLINE) presents a detailed analysis of current animal models and gives recommendations for future experimental research. Special consideration should be given to cytotoxic drug dose and concentration, tumor models, and outcome parameters.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  HIPEC; animal experimentation; colorectal carcinoma; cytoreductive surgery; peritoneal metastasis

Mesh：

Substances：

Year:  2013        PMID： 24122416     DOI： 10.1002/jso.23464

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  8 in total

1.  Normothermic and Hyperthermic Intraperitoneal Chemoperfusions with Cisplatin to Treat Advanced Ovarian Cancer in Experimental Settings.

Authors:  G S Kireeva; V G Bespalov; O A Belyaeva; K Y Senchik; A N Stukov; G I Gafton; K D Guseynov; A M Belyaev
Journal:  Pathol Oncol Res       Date:  2017-01-23       Impact factor: 3.201

2.  Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy.

Authors:  Clarisse Eveno; Aminata Haidara; Ibrahim Ali; Cynthia Pimpie; Massoud Mirshahi; Marc Pocard
Journal:  Pleura Peritoneum       Date:  2017-05-25

3.  Murine Models of Intraperitoneal Perfusion for Disseminated Colorectal Cancer.

Authors:  Eleanor McCabe-Lankford; Margarita Peterson; Bryce McCarthy; April J Brown; Brad Terry; Laura Galarza-Paez; Nicole Levi-Polyachenko
Journal:  J Surg Res       Date:  2018-09-05       Impact factor: 2.417

4.  Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.

Authors:  Félix Gremonprez; Benedicte Descamps; Andrei Izmer; Christian Vanhove; Frank Vanhaecke; Olivier De Wever; Wim Ceelen
Journal:  Oncotarget       Date:  2015-10-06

5.  Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization.

Authors:  Lieselotte Lemoine; Elsy Thijssen; Robert Carleer; Jirka Cops; Veerle Lemmens; Peter Van Eyken; Paul Sugarbaker; Kurt Van der Speeten
Journal:  Oncotarget       Date:  2019-02-15

6.  Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.

Authors:  Kaat De Clercq; Feifan Xie; Olivier De Wever; Benedicte Descamps; Anne Hoorens; An Vermeulen; Wim Ceelen; Chris Vervaet
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

7.  Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model.

Authors:  Nick Seyfried; Can Yurttas; Markus Burkard; Benedikt Oswald; Alexander Tolios; Franziska Herster; Joseph Kauer; Tarkan Jäger; Ingmar Königsrainer; Karolin Thiel; Markus Quante; Hans-Georg Rammensee; Sascha Venturelli; Matthias Schwab; Alfred Königsrainer; Stefan Beckert; Markus W Löffler
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

8.  BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.

Authors:  Wouter Willaert; Kurt Van Der Speeten; Gabriel Liberale; Wim Ceelen
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.